NB that I did post my dietary info for a representative week, including:
i noticed you have no fish oil or flax/borage oil. any thoughts on this? do you get it through your diet?
... and I specifically recommend that people on CR favor ALA (eg flax) over long-chain omega-3s (EPA/DHA/fatty fish), which has cardiovascular outcomes at least as favorable and doesn't potentially undermine CR's effects on mitochondrial inner membrane composition, as outlined (badly out of date!) eg here; for a semi-update , see references (1-15) here.
Saturated | 9.5 g
Monounsaturated | 39.5 g
Polyunsaturated | 20.9 g
Omega-3 | 7.6 g 190%
Omega-6 | 13.2 g
Trans-Fats | 0.0 g
Cholesterol | 30.8 mg 10%
Phytosterol | 136.2 mg
It's also worth noting that the CVD benefits of omega-3 of any form are actually (and very surprisingly) somewhat in doubt (3).
Your surprise seems to imply that you think everybody has gut dysbiosis . And, FWIW, I've been consuming home-brew kefir for > 7 yrs.
I'm also surprised not to see any probiotics on this list. Seems like a no-brainer.
Caught . Yes, this is quite inconsistent. I can't really justify it: I do need a B12 supplement, I'm enamored of the apparent neurological benefits (not absolutely clearly better than cyano- , and not clearly sensible at this dose vs non-deficient or multi-mg megadose as in neurological disease trials), and gawrsh, it sure looks safe .
I am more interested in the rationale behind the 1mg sublingual methylcobalamin, an exponentially higher dose than the RDA
You're a sample size of 1; you have a specific condition which most people don't have; you've been taking it for what -- 3-5 years? -- certainly not a lifetime as a putative anti-aging agent for healthy humans; and, yes, there is the placebo effect.Yet I have found nothing with as positive an effect for me on osteoarthritis.
[Resveratrol is] a substance of unkown benefits even on those select few endpoints in rodents (much less knowing whether any of the data translates to humans!) and the additional drawback of zero safety data for chronic use. High doses of resveratrol are basically untested. [b]You'd be taking an experimental drug that was never tested in humans.
Celebrex looked quite fine in the preclinical studies, and actually, it's no safer in the real world even for GI bleeds and ulcers than other NSAIDs, with the contrary illusion created by selective reporting (1,2) and aggressive marketing -- and, of course, it took many years after approval, and use in physician-monitored patient populations of thousands, to uncover the cardiovascular side effects.
Even were celebrex to as effective, its long-term effects are even more worisome, and that is perhaps the safest of the high-power drugs in the rheumatoligists' arsenal. At least resveratrol did not shorten life expectancy in that study.
Statins cause myalgia in perhaps 1-5% of patients, and analyses of large patient databases from FDA (4) and large HMOs (5) found a rate of actual rhabdomyolysis from monotherapy in currently-approved statins to be ≤ 1.18 per 100,000 prescriptions -- though muscle damage visible on electron microscopy and other analyses persists in patients who discontinue following myalgia symptoms alone (6) To take a more extreme example, < 1 in 10 long-term smokers develop lung cancer, and it takes decades to show up. There is a reason why, even accounting for Big Tobacco malfeasance, the association was not well-established until well into the late 20th century.
1. Therapeutics initiative for evidence-based drug therapy. COX-2 inhibitors update: Do journal publications tell the full story? Ther Letter 2001–2002; 43(Nov-Dec/Jan):1-2.
2. Wooltorton E. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ. 2002 Jun 25;166(13):1692-3.
PubMed PMID: 12126328; PubMed Central PMCID: PMC116160.
3. León H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008 Dec
23;337:a2931. doi: 10.1136/bmj.a2931. Review. PubMed PMID: 19106137
4. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase
inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004
Jul;13(7):417-26. PubMed PMID: 15269925.
5. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz
JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in
patients treated with lipid-lowering drugs. JAMA. 2004 Dec 1;292(21):2585-90.
Epub 2004 Nov 22. PubMed PMID: 15572716.
6. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L,
Hoppeler H, Breil F, Draeger A. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009 Jul 7;181(1-2):E11-8. PubMed PMID:
19581603; PubMed Central PMCID: PMC2704421.
Edited by Michael, 31 December 2009 - 10:47 PM.
Adding statin example